{"id":68050,"date":"2026-06-12T14:07:43","date_gmt":"2026-06-12T06:07:43","guid":{"rendered":"https:\/\/flcube.com\/?p=68050"},"modified":"2026-06-12T14:07:44","modified_gmt":"2026-06-12T06:07:44","slug":"cascade-pharmaceuticals-secures-rmb-318-million-series-d-financing-to-advance-bile-acid-metabolism-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68050","title":{"rendered":"Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Cascade Pharmaceuticals, Inc.<\/strong>, a Shanghai-based sino-foreign joint venture biotechnology company, has secured <strong>RMB 318 million (USD 47 million)<\/strong> in a <strong>Series D financing round<\/strong>. The round was <strong>co-led by Taiping Medical Health Fund and Shanghai Technology Venture Capital Group<\/strong>, with participation from several professional investment institutions including <strong>Yuekai Capital, Zhaode Investment, and Lianbang Fund<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-financing-details\" class=\"wp-block-heading\">Financing Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Amount Raised<\/strong><\/td><td>RMB 318 million (USD 47 million)<\/td><\/tr><tr><td><strong>Round<\/strong><\/td><td>Series D<\/td><\/tr><tr><td><strong>Lead Investors<\/strong><\/td><td>Taiping Medical Health Fund, Shanghai Technology Venture Capital Group<\/td><\/tr><tr><td><strong>Participating Investors<\/strong><\/td><td>Yuekai Capital, Zhaode Investment, Lianbang Fund<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Clinical advancement of core pipeline and continued upgrading of R&amp;D systems<\/td><\/tr><tr><td><strong>Company Status<\/strong><\/td><td>Clinical-stage biotechnology company<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2017<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-company-profile-amp-therapeutic-focus\" class=\"wp-block-heading\">Company Profile &amp; Therapeutic Focus<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Focus Area:<\/strong> Diseases related to <strong>bile acid metabolism disorders<\/strong><\/li>\n\n\n\n<li><strong>Technology Approach:<\/strong> <strong>Structure-driven drug design<\/strong> and <strong>first-principles thinking<\/strong><\/li>\n\n\n\n<li><strong>Pipeline Strategy:<\/strong> Differentiated portfolio spanning indications from <strong>primary biliary cholangitis (PBC)<\/strong> and <strong>metabolic dysfunction-associated steatohepatitis (MASH)<\/strong> to <strong>obesity<\/strong> and <strong>diabetes<\/strong><\/li>\n\n\n\n<li><strong>Product Potential:<\/strong> Core candidates possess <strong>first-in-class<\/strong> and <strong>best-in-class<\/strong> potential<\/li>\n\n\n\n<li><strong>Corporate Structure:<\/strong> Sino-foreign joint venture headquartered in Shanghai<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Clinical Development<\/strong><\/td><td>Accelerated advancement of lead candidates through pivotal trials<\/td><\/tr><tr><td><strong>R&amp;D Infrastructure<\/strong><\/td><td>Enhanced capabilities for structure-based drug discovery and optimization<\/td><\/tr><tr><td><strong>Market Position<\/strong><\/td><td>Strengthened competitive stance in metabolic disease therapeutics<\/td><\/tr><tr><td><strong>Investor Confidence<\/strong><\/td><td>Strong backing from both strategic healthcare funds and technology-focused VCs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The financing reflects growing investor confidence in Cascade&#8217;s innovative approach to targeting bile acid metabolism pathways, which play critical roles in liver function, glucose homeostasis, and lipid metabolism.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-outlook\" class=\"wp-block-heading\">Market Context &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Metabolic Disease Landscape:<\/strong> The global market for metabolic disorder treatments is projected to exceed <strong>USD 100 billion by 2030<\/strong>, driven by rising prevalence of obesity, diabetes, and fatty liver diseases<\/li>\n\n\n\n<li><strong>Therapeutic Gap:<\/strong> Current treatments for PBC and MASH offer limited efficacy, creating significant opportunities for novel mechanism-based therapies<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Cascade&#8217;s <strong>structure-driven approach<\/strong> enables precise targeting of bile acid receptors and enzymes, potentially yielding superior safety and efficacy profiles<\/li>\n\n\n\n<li><strong>Geographic Strategy:<\/strong> As a <strong>sino-foreign joint venture<\/strong>, Cascade is well-positioned to pursue parallel development paths in both Chinese and international markets<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financing use, clinical development timelines, and market opportunities. Actual results may differ due to risks including regulatory approvals, clinical trial outcomes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture biotechnology company, has secured RMB 318 million&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68052,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[2399,20],"class_list":["post-68050","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cascade-pharmaceuticals","tag-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture biotechnology company, has secured RMB 318 million (USD 47 million) in a Series D financing round. The round was co-led by Taiping Medical Health Fund and Shanghai Technology Venture Capital Group, with participation from several professional investment institutions including Yuekai Capital, Zhaode Investment, and Lianbang Fund.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68050\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline\" \/>\n<meta property=\"og:description\" content=\"Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture biotechnology company, has secured RMB 318 million (USD 47 million) in a Series D financing round. The round was co-led by Taiping Medical Health Fund and Shanghai Technology Venture Capital Group, with participation from several professional investment institutions including Yuekai Capital, Zhaode Investment, and Lianbang Fund.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68050\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-12T06:07:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-12T06:07:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1201.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68050#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68050\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline\",\"datePublished\":\"2026-06-12T06:07:43+00:00\",\"dateModified\":\"2026-06-12T06:07:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68050\"},\"wordCount\":384,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68050#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1201.webp\",\"keywords\":[\"Cascade Pharmaceuticals\",\"Finance\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68050#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68050\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68050\",\"name\":\"Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68050#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68050#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1201.webp\",\"datePublished\":\"2026-06-12T06:07:43+00:00\",\"dateModified\":\"2026-06-12T06:07:44+00:00\",\"description\":\"Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture biotechnology company, has secured RMB 318 million (USD 47 million) in a Series D financing round. The round was co-led by Taiping Medical Health Fund and Shanghai Technology Venture Capital Group, with participation from several professional investment institutions including Yuekai Capital, Zhaode Investment, and Lianbang Fund.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68050#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68050\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68050#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1201.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1201.webp\",\"width\":1080,\"height\":608,\"caption\":\"Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68050#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture biotechnology company, has secured RMB 318 million (USD 47 million) in a Series D financing round. The round was co-led by Taiping Medical Health Fund and Shanghai Technology Venture Capital Group, with participation from several professional investment institutions including Yuekai Capital, Zhaode Investment, and Lianbang Fund.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68050","og_locale":"en_US","og_type":"article","og_title":"Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline","og_description":"Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture biotechnology company, has secured RMB 318 million (USD 47 million) in a Series D financing round. The round was co-led by Taiping Medical Health Fund and Shanghai Technology Venture Capital Group, with participation from several professional investment institutions including Yuekai Capital, Zhaode Investment, and Lianbang Fund.","og_url":"https:\/\/flcube.com\/?p=68050","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-12T06:07:43+00:00","article_modified_time":"2026-06-12T06:07:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1201.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68050#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68050"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline","datePublished":"2026-06-12T06:07:43+00:00","dateModified":"2026-06-12T06:07:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68050"},"wordCount":384,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68050#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1201.webp","keywords":["Cascade Pharmaceuticals","Finance"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68050#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68050","url":"https:\/\/flcube.com\/?p=68050","name":"Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68050#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68050#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1201.webp","datePublished":"2026-06-12T06:07:43+00:00","dateModified":"2026-06-12T06:07:44+00:00","description":"Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture biotechnology company, has secured RMB 318 million (USD 47 million) in a Series D financing round. The round was co-led by Taiping Medical Health Fund and Shanghai Technology Venture Capital Group, with participation from several professional investment institutions including Yuekai Capital, Zhaode Investment, and Lianbang Fund.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68050#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68050"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68050#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1201.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1201.webp","width":1080,"height":608,"caption":"Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68050#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1201.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68050"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68050\/revisions"}],"predecessor-version":[{"id":68053,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68050\/revisions\/68053"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68052"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}